BYETTA, JANUVIA, AND JANUMET DIABETES DRUGS LINKED TO CANCERS

Written By: Rheingold, Valet, Rheingold, Ruffo & Giuffra LLP

Jan 21, 2013

As we continue our firm's litigation for Actos bladder cancer clients, there is a medical study now linking other diabetes drugs to cancer: Byetta to pancreatic and thyroid cancers, and Januvia/Janumet to pancreatic cancers. A medical team at the University of California, Los Angeles, published a study in the Gastroenterology Medical Journal finding a statistically significant increased pancreatic cancer risk (Byetta 2.9-fold, Januvia/Janumet 2.7-fold), as well as a 4-fold increase for thyroid cancer in Byetta users. Thyroid cancer was originally found in pre-market animal studies. These drugs are associated with substantial increases in pancreatitis, a dangerous inflammation in the pancreas. Inflammation is associated with increased cancer risk, and the medical researchers have surmised that these drugs stimulate pre-cancerous cells which would otherwise be harmless. Both Paul and David Rheingold are are using their Actos bladder litigation experience to evaluate potential claims for Byetta and Januvia/Janumet users.

Categories:

Don't Settle

for an Average Attorney

- Name:
  
  Please enter your name.
- Phone
  
  This isn't a valid phone number.
- Email:
  
  Please enter your email address.
  
  This isn't a valid email address.
- Are you a new client?
  
  Please make a selection.
- Message
  
  Please enter a message.

Get RGRP On Your Side